TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06560489
Drug: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Study: NCT05007236
Drug: RP7214 + Standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP7214 tablets will be administered orally twice a day for 14 days
Study: NCT05007236
Drug: Placebo + Standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally twice a for 14 days
Study: NCT05314621
Drug: olopatadine hydrochloride ophthalmic solution 0.7%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pataday® Once Daily Relief Extra Strength (eyedrop)
Study: NCT05314621
Drug: Saline nasal spray
Normalized name: Saline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline nasal spray (nasal spray)
Study: NCT05911984
Drug: 9MW3811 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05258721
Drug: ClōSYS® Sensitive Fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.
Study: NCT05415137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion every 4 weeks for a total of 12 doses
Study: NCT04757766
Drug: in daily everyday routine practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment of patients with chronic venous disease of CEAP classes C6 will be consistent with routine clinical practice, local label for the medical use of drugs and the specific clinical situation.
Study: NCT04996160
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2/dose IV
Study: NCT05977868
Drug: Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid
Approvals — FDA: no, EMA: no, PMDA: no
Description: COpAT (oral antimicrobial therapy) on hospital discharge
Study: NCT03365414
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Normal Saline 0.9% Infusion Solution Bag.
Study: NCT05276063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken twice daily by mouth
Study: NCT05663710
Drug: ArabinoFuranosylGuanine [18F]F-AraG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05814406
Drug: JW0201
Approvals — FDA: no, EMA: no, PMDA: no
Description: JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
Study: NCT05814406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
Study: NCT05101317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06512584
Drug: PJ009 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injections, once daily
Study: NCT04761302
Drug: Intravenous ketorolac and oral acetaminophen
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group
Study: NCT05658003
Drug: ARDT
Normalized name: CHLAMYDOMONAS REINHARDTII
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally on a continuous basis, as per package insert and guidelines
Study: NCT05658003
Drug: [68Ga]Ga-PSMA-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
Study: NCT05288283
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT05288283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT05814107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of Placebo
Study: NCT05653258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a placebo (methylcellulose) to provide a similar mass, number of tablets/ capsules, and frequency as the senolytic arm.
Study: NCT05509790
Drug: LY3484356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06667765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose formulation- Oral capsule
Study: NCT06215911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06798038
Drug: phenol neurolysis
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 Patients will be administered with 2.0 ml of 6% phenol solution prepared from crystallized phenol per genicular nerve
Study: NCT06799650
Drug: Gammora®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gammora® SC + Tenofovir/3TC + darunavir+ritonavir
Study: NCT05781152
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
Study: NCT06790121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
Study: NCT06788431
Drug: Optimal medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group subjects receive only optimal medical treatment.
Study: NCT06788431
Drug: Optimal medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group subjects also receive optimal medical treatment
Study: NCT06792474
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion
Study: NCT06787118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo for a total of 12 weeks.
Study: NCT05318534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration route: intravenous infusion and subcutaneous injection
Study: NCT06785987
Drug: intermittent fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.
Study: NCT06783868
Drug: Market-approved AVNB, OAC and AAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used per protocol for the duration of the trial.
Study: NCT06788366
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line regimen according to clinical practice
Study: NCT06788366
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line regimen according to clinical practice
Study: NCT06163989
Drug: TheaLoz Duo Eyedrop
Normalized name: Effaclar Duo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TheaLoz Duo lubricating eyedrop contains 3.0% trehalose and 0.15% sodium hyaluronate as active ingredients and will be used by participants everyday to instill 1 drop, 4 times a day in both eyes.
Study: NCT05552326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen-matching placebo will be administered by SC injection.
Study: NCT06062030
Drug: DWJ1609
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug of test group
Study: NCT06062030
Drug: DWC202304
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug of control group
Study: NCT06783335
Drug: Standard of Care Pharmacologic Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Patients with chronic heart failure who receive standard medical care without PA pressure monitoring~* These patients will be monitored for 2 years~* Patients must be on guideline-directed medical therapy appropriate for their ejection fraction status
Study: NCT06792435
Drug: XNW27011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent.~An accelerated titration scheme will be used for the first two dose levels (0.6 mg/kg and 1.2 mg/kg) starting from 0.6 mg/kg dose as follows:~The first patient will be enrolled for 0.6 mg/kg dose. If the subject shows no significant toxicity in cycle 1 (DLT observation period), the second patient will be enrolled for 1.2 mg/kg.~3 + 3 dose escalation:3 patients will be enrolled to the dose cohort first，If 1 of 3 patients experiences a DLT, up to 3 more patients will be enrolled in the same dose cohort.. If none of the additional 3 patients experiences a DLT, dose escalation will continue to the next dose.Dose escalation will be stopped when 2 or more patients out of 3 to 6 patients at the same dose level experience a DLT.
Study: NCT06792435
Drug: XNW27011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Gastric/gastroesophageal junction adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group B: Pancreatic adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group C: Ovarian cancer with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group D: Other tumors with CLDN18.2 expression, including but not limited to esophagus adenocarcinoma, lung cancer, colorectal cancer, and biliary tract cancer,tentatively expand with 3.6, 3.0, 2.4 mg/kg.
Study: NCT06148272
Drug: LY3971297
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06148272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04978597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of to matching placebo, Oral. Swallow whole with water, once daily at bedtime at least 1 hour after L-DOPA/DDCI
Study: NCT05583526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule
Study: NCT06784570
Drug: adrenaline,noreadrenaline,dopamine and doputamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9
Study: NCT06321562
Drug: TimoD implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consists of 1 TimoD implant administration in the study eye
Study: NCT05509400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DB Phase: matching placebo
Study: NCT06787885
Drug: Levofloxacin + clindamycin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1
Study: NCT05768360
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study: NCT06118021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06441643
Drug: PG043 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational fixed dose combination supplied in two concentration levels: low and high
Study: NCT05079919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olezarsen-matching placebo will be administered by SC injection.
Study: NCT06447519
Drug: Ca(OH)2 as intracanal medicament
Normalized name: CITRUS MEDICA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH2 will be used as intracanal medicament for the disinfection of the root canal between appointmnents
Study: NCT06789861
Drug: Placebo - TT5 vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of vehicule, according to the same drug regimen than TT5
Study: NCT06221150
Drug: Bilateral two level serratus anterior block
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bilateral two-level SAPB will be performed with the guidance of ultrasound. While the patient is in the supine position with their arms abducted, the ribs will be counted down from the second rib at the level of manubriosternal joint, the mid- axillary line will be demarcated where the probe will be placed in the longitudinal plane to visualize the ribs and the overlying muscles. Using in- plane approach, a 22-gauge short bevel needle will be inserted and advanced to the plane between the latissimus dorsi muscle and the serratus muscle under sono-visualization at the level of 3rd and 6th ribs bilaterally in succession over which a total volume of 1ml/kg bupivacaine 0.25% will be divided and injected (0.5ml/kg on each side); with total dose not exceeding 2.5 mg/kg
Study: NCT05760261
Drug: GSK3882347
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3882347 will be administered.
Study: NCT06310200
Drug: Bitrex
Normalized name: Bitrex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bittering agent
Study: NCT06310200
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05272878
Drug: Placebo, tablet, 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
Study: NCT05477459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with equal appearance
Study: NCT05432388
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT05804591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule containing placebo per os 1 hour before start of the operation.
Study: NCT04743934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually identical placebo tablets taken by mouth daily at bedine
Study: NCT04743934
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
Study: NCT05286554
Drug: gonadotropin releasing hormone-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT06030609
Drug: Ringer's Lactate Crystalloid Solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive RLS as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
Study: NCT06030609
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive NSS with D5W as a replacement fluid for urine output (mL per mL) until the patient have sufficient oral intake and fluid can be removed.
Study: NCT05324462
Drug: IDegLira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collecting data reported in medical records of patients with T2D, who had initiated treatment with commercially available IDegLira according to the routine clinical practice and local label at the discretion of the treating physician
Study: NCT04877613
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepletion
Study: NCT06474676
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT06474676
Drug: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
Normalized name: HUMAN BREAST TUMOR CELL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05764265
Drug: LTP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTP001 will be administered orally once daily in the morning
Study: NCT06166992
Drug: [14C]-BI 1291583
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-BI 1291583
Study: NCT05992883
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
Study: NCT05322707
Drug: Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol
Normalized name: Symbicort, 80 mcg-4.5 mcg/inh inhalation aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily
Study: NCT05322707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily
Study: NCT05253833
Drug: AR882 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Capsule
Study: NCT05253833
Drug: AR882 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Capsule
Study: NCT04564898
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days
Study: NCT04564898
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days
Study: NCT06752382
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.
Study: NCT06751914
Drug: Neoantigen-based peptide vaccine
Normalized name: covid-19, RNA-based vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study: NCT05947955
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration in the same volume as the active therapy
Study: NCT06528444
Drug: Grup 1 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 capsule (6 mg) /day for 7 days.
Study: NCT05090124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
Study: NCT06459310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets, 1000 mg/day, single dose
Study: NCT04923542
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
Study: NCT06206408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05579327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be identical in appearance to tiratricol tablets but contain no tiratricol. Treatment will be administered orally or via PEG tube; tablets will be suspended in water and, if needed, mixed with mashed food for oral administration or administered in water through the PEG tube as applicable. During the Randomized Treatment Period, participants will receive the same number of tablets as the stable dose of open-label tiratricol they were receiving before randomization.
Study: NCT06250205
Drug: Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT06250205
Drug: Drospirenone / Ethinyl Estradiol (COC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05133297
Drug: TLL-018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at dose1 BID daily for 24 weeks.
Study: NCT05133297
Drug: TLL-018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at dose2 BID daily for 24 weeks.
Study: NCT05133297
Drug: TLL-018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at dose3 BID daily for 24 weeks.
Study: NCT05214482
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion,Specified dose on specified days
Study: NCT04836429
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo photodynamic therapy
Study: NCT05790707
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
Study: NCT05400967
Drug: 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22GBq(60mci) 177Lu-EB-FAPI was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Study: NCT05892432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A medically inert placebo medication will be taken for 8 weeks.